ULTRAISER Clinic (eHM15)

The HIFU ULTRAISER Pen System eHM15 is a professional non-invasive skin-lifting and fat-reduction device for beauty clinics. It is explicitly not a home-use device. It uses focused ultrasound to deliver thermal energy into the dermis and the SMAS layer, producing coagulative necrosis that triggers new collagen formation for tightening - and it also targets subcutaneous fat for breakdown as part of body-shaping protocols. **Key points:** - Modality: HIFU (high-intensity focused ultrasound) using a pen-type handpiece system. - Depth targeting: energy is delivered to the dermis or SMAS; the listing also describes subcutaneous fat targeting for fat reduction. - Effect mechanism: coagulative necrosis of the target tissue followed by new collagen formation - the classic HIFU lifting pathway. - Positioning: professional clinic use, expressly not for home use. - Dual application: facial skin lifting plus body shaping and fat reduction from one platform. **Business case:** A single HIFU platform covering both face (lifting) and body (fat reduction) lets a clinic market two distinct service lines - an anti-aging facial menu and a body contouring menu - from one capital purchase and one trained operator, which materially improves utilisation of both the room and the device. **Confidence:** High - modality, mechanism, depth target and clinic-only positioning are all stated in the product record. **Evidence source:** Product listing `ultraiser-clinic-ehm15` (id=1163), fields: lede, what_it_is, how_it_works, who_for.

The FDA/regulatory status of the ULTRAISER Clinic eHM15 cannot be confirmed from the current product data. The structured regulatory fields `fda_key`, `fda_label` and `fda_tone` are empty, and the listing text contains no FDA clearance, CE marking or other regulatory claim. Do not assume clearance - and equally, do not assume the absence of clearance - on the basis of this record. **Key points:** - `fda_key`, `fda_label` and `fda_tone` are all empty on the product record. - No clearance or certification statement (FDA, CE, Health Canada, TGA, UKCA) appears anywhere in the listing text. - HIFU platforms for aesthetic lifting typically reach the US market via 510(k) premarket notification as Class II devices - so if a claim is made, the correct word is 'cleared', not 'approved'. - The listing does state the device is for professional clinic use only, not home use - a safety/positioning statement, not a regulatory one. **⚠️ FLAG - procurement verification required.** Before purchase, obtain from the supplier: (1) the 510(k) clearance number and cleared indications if a US claim is made, (2) CE marking documentation to EU MDR 2017/745 or UKCA evidence for European deployment, (3) a signed regulatory status letter on company letterhead covering the exact model/serial range being purchased, (4) electrical safety certification (IEC 60601-1) and, for training, the manufacturer's clinical protocol and consumable/handpiece lifecycle statement. **Business case:** HIFU is a high-ticket capital purchase with real indemnity exposure if clearance cannot be demonstrated; a signed regulatory status letter is a prerequisite for insurance cover in most markets. **Confidence:** Low - no FDA or equivalent regulatory information of any kind is present in the product data, so no status can be stated. **Evidence source:** Product listing `ultraiser-clinic-ehm15` (id=1163), fields: fda_key, fda_label, fda_tone, lede, what_it_is, how_it_works, who_for (all regulatory fields empty).

The product record describes the HIFU mechanism but does not publish a session schedule. Use the standard HIFU protocol for this device class and confirm the exact parameters with the manufacturer's clinical protocol: a single treatment with a follow-up assessment at 8-12 weeks, or a course of 2-3 sessions spaced 4-6 weeks apart for more advanced laxity, then maintenance every 6-12 months. **Key points:** - Course: typically 2-3 sessions at 4-6 week intervals for facial lifting; body/fat-reduction areas often need a 3-4 session course. - Response timeline: collagen neosynthesis after HIFU peaks at roughly 8-12 weeks, so clinical photography should be scheduled at baseline and 12 weeks, not 1 week. - Downtime: generally 0-2 days of mild redness, swelling or tenderness - far lower than surgical lifting, which is the main marketing angle. - Maintenance: one session every 6-12 months keeps the lifted result. - Transducer/handpiece life and depth cartridges are the key running-cost variable - confirm the replacement schedule in writing. **Business case:** HIFU's 8-12 week response curve is an asset if managed properly: pre-book the 12-week review and the maintenance session at the time of the first treatment, lock in two follow-up appointments per client and turn a single high-ticket sale into an annual relationship. **Confidence:** Medium - the HIFU mechanism and deep collagen response are documented in the record; the specific session count and intervals are standard clinical practice for HIFU platforms rather than published device specifications. **Evidence source:** Product listing `ultraiser-clinic-ehm15` (id=1163), fields: lede, what_it_is, how_it_works, who_for.

The listing publishes no Fitzpatrick skin-type restriction or contraindication table for the ULTRAISER Clinic eHM15. Because HIFU works by focused thermal coagulation at depth, treating Fitzpatrick IV-VI skin requires deliberate parameter reduction and close post-treatment monitoring for post-inflammatory hyperpigmentation (PIH) and, in higher-energy protocols, burns. **Key points:** - No Fitzpatrick range or skin-type suitability claim appears anywhere in the product data. - Fitzpatrick IV-VI: start at the lowest therapeutic energy, increase spacing between lines, avoid over-lapping transducer passes and use cooling - thermal injury in darker skin has a higher PIH risk. - Depth selection matters: 4.5 mm (SMAS) and 3.0 mm (deep dermis) transducers carry more thermal load than superficial 1.5 mm transducers - stage deeper treatment after a test session. - Screening contraindications to document: pregnancy, open lesions or infection in the treatment area, implants or metal in the treatment path, keloid tendency, and anticoagulant use. - Take standardised baseline photography - the 8-12 week HIFU response must be judged against an objective baseline. **Business case:** Photographic documentation and a staged first session are what protect a HIFU service from disputes; the treatment is expensive enough that dissatisfied clients escalate quickly when a cosmetic adverse event is not documented. **Confidence:** Low to Medium - the absence of any skin-type claim is confirmed from the record; the Fitzpatrick IV-VI guidance is standard clinical practice for focused-ultrasound devices and is not product-documented. **Evidence source:** Product listing `ultraiser-clinic-ehm15` (id=1163), fields: lede, what_it_is, how_it_works, who_for.